-
2024 North-South Summit丨Professor Leiping Wang: Is Neoadjuvant Immunotherapy the Future for HR+/HER2- Breast Cancer?
HR+/HER2- is the most common subtype of breast cancer, which is not highly sensitive to neoadjuvant therapy. In 2023, clinical trial results from KEYNOTE-756, CheckMate 7FL, and other studies presented at international conferences showed the potential of neoadjuvant immunotherapy for early-stage HR+/HER2- breast cancer patients. At the 2024 North-South Summit, Professor Leiping Wang from Fudan…
-
2024 North-South Summit丨Professor Jia Wang: Should Contralateral Prophylactic Mastectomy Be Considered for gBRCA-Mutated Breast Cancer?
Among breast cancer patients, 5% to 10% have definite genetic mutations, with gBRCA1/2 mutations accounting for 15% of these cases. Individuals with gBRCA1 mutations have a higher risk of contralateral breast cancer recurrence, making the decision to undergo contralateral prophylactic mastectomy (CPM) a hot topic of discussion. At the 2024 North-South Summit, Professor Jia Wang…
-
Professor Ting Luo: Feasibility of Sequential ADC Treatment in Advanced Breast Cancer: ADC After ADC?丨2024 North-South Meeting
With the continuous development and market release of new ADC drugs, the treatment landscape for breast cancer patients has changed. For patients with advanced breast cancer, the feasibility of using another ADC drug after the initial ADC treatment has become a common clinical concern. In the “In-depth Inquiry” segment of the 2024 North-South Meeting, Professor…
-
EAU24 International Perspective丨Professor Thomas Powles: ADC Combined with Immunotherapy Poised to Reshape Urothelial Carcinoma Treatment
Urothelial carcinoma is one of the most common malignancies of the urinary system, with high incidence and mortality rates. Despite the efficacy of platinum-based chemotherapy as the standard first-line treatment for advanced urothelial carcinoma, researchers have been relentless in their pursuit of more effective and personalized treatment options. Recent breakthroughs in targeted therapies and immunotherapies…
-
2024 South-North Forum | Prof. Li Ma: Is Robotic Surgery Necessary for Early-Stage Breast Cancer?
The prevalence of robotic surgery in the treatment of early-stage breast cancer is not high, and there is significant debate over its necessity for these patients. At the 2024 South-North Forum, Prof. Li Ma from The Fourth Hospital of Hebei Medical University delivered a presentation on the topic “Is Robotic Surgery Necessary for Early-Stage Breast…
-
EAU24 Expert Review | Professor Qiang Wei: Multimodal Treatment of Renal Cancer from a Surgical Perspective
The treatment of renal cancer includes surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. With advancements in treatment technologies, combining the latest modalities for comprehensive treatment of renal cancer is crucial for improving prognosis. The 39th Annual European Association of Urology (EAU24) Congress was held from April 5-8, 2024, in Paris, France, focusing on global urological…
-
Professor Wenbin Qian: Mechanisms of CAR-T Cell Therapy Resistance and Countermeasures | 2024 Nanjing Lymphoma Forum
Chimeric Antigen Receptor T-cell Therapy (CAR-T) is a novel cellular immunotherapy technology that has shown excellent efficacy in the treatment of refractory relapsed diffuse large B-cell lymphoma (DLBCL). Despite this, a significant number of patients do not respond to the treatment or experience relapse and progression. How to further improve the efficacy of CAR-T cells…
-
Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis
The “Hepatology Digest – Liver Vascular Diseases” column is a scholarly column co-initiated by Dr. Xingshun Qi from the Department of Gastroenterology at the General Hospital of Northern Theater Command, at the invitation of the editorial board of Hepatology Digest. This column regularly collects and summarizes research progress in the field of liver vascular diseases,…
Connecting Medical Expertise through Media